Santen Pharmaceutical : Announces Change of Representative Director of the Board

March 23, 2022

Santen Announces Change of Representative Director of the Board

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; President and CEO: Shigeo Taniuchi; hereinafter, the "Company") today announced that its Board of Directors has approved the following management changes as described below.

1. Reason for changes

Santen previously announced its new Executive Management Team (herein after "EMT") effective on April 1st, 2022. The newly formed EMT aims to enhance its competitiveness as a global company, increasing the capability of strategy implementation and realizing even greater growth over the medium to long-term. Appointment of the Representative Director of the Board, Executive Vice President will enable Santen to integrate expertise and insight of its core businesses including Japan into global strategic execution and further transform the Company into a truly global organization.

2. Details of the change effective April 1

	Name	Newly Appointed	Current Position
	Akira Kurokawa	Director of the Board,	Representative Director of the
	Chairman	Board, Chairman
		Representative Director of the Board,	Director of the Board, Executive
	Takeshi Ito	Executive Vice President, Head of	Corporate Officer, Head of Japan
	Japan Business, Head of Japan	Business, Head of Japan Sales and
		Sales and Marketing Division	Marketing Division
3. Profile of the New Representative Director of the Board, Executive Vice President
Name	Takeshi Ito
Number of Shares held	23,554 (as of March, 2022)

Profile

Apr 1982 Joined the Company

Dec 2002 Head of R&D Integration Department, R&D Division

Apr 2007 Head of Surgical Division

Apr 2012 Corporate Officer, Head of Prescription Pharmaceuticals Sales Department, Sales &Marketing Division, Prescription Pharmaceuticals

Apr 2014 Senior Corporate Officer, Head of Japan Sales & Marketing Division, Prescription Pharmaceuticals

Apr 2016 Executive Corporate Officer, Japan Business, Head of Japan Sales & Marketing Division, Prescription Pharmaceuticals

Jun 2017 Director of the Board, Executive Corporate Officer, Japan Business, Head of Japan Sales & Marketing Division, Prescription Pharmaceuticals

Apr 2019 Director of the Board, Executive Corporate Officer, Head of Japan Business, Head of Japan Sales & Marketing Division (incumbent)

(Reason for appointment)

Ito is a seasoned executive with a deep understanding of Santen CORE PRINCIPLE and its sprit behind. With a wealth of experience including Research and Development, surgical and pharmaceuticals business, he has led the Japanese business as part of core businesses at Santen, serving as Director of the Board, Executive Corporate Officer, Head of Japan Business, Head of Japan Sales & Marketing Division since 2019. In this position, Ito will lead the strategy and execution to roll-out global products through his expertise of customer-centric marketing and planning.

4. Timing of implementation April 1, 2022

Contact:

Kaori Itagaki

General Manager, IR Group

E-mail:[e-mail]: [phone]

About Santen

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries.

Toward realizing "WORLD VISION" (Happiness with Vision), the world Santen ultimately aspires to achieve, as a "Social Innovator", we aim to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world.

With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.

For more information, please visit Santen's website ( https://www.santen.com/en/).